Antiproteinuric Effects of Liraglutide Treatment

NCT02545738 on ClinicalTrials.gov · last registry update 2016-08-10

A small phase 4 — 32 participants, against a typical 75. The sponsor logged completion for May 2016. Primary outcome, as filed: Change in albuminuria. liraglutide is approved in the US, but not for diabetic kidney disease — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Steno Diabetes Center Copenhagen
Sponsor type: Other
Enrollment: 32
Started: 2015-04
Primary completion: 2016-05 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in albuminuria

Conditions studied

Diabetic Kidney Disease

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.